PE20181090A1 - Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 - Google Patents
Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38Info
- Publication number
- PE20181090A1 PE20181090A1 PE2017002833A PE2017002833A PE20181090A1 PE 20181090 A1 PE20181090 A1 PE 20181090A1 PE 2017002833 A PE2017002833 A PE 2017002833A PE 2017002833 A PE2017002833 A PE 2017002833A PE 20181090 A1 PE20181090 A1 PE 20181090A1
- Authority
- PE
- Peru
- Prior art keywords
- num
- sec
- ident
- antibodies
- treatment
- Prior art date
Links
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 title abstract 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000008102 immune modulation Effects 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Referido a metodos para la inmunomodulacion con anticuerpos que se unen especificamente a CD38, caracterizado porque el anticuerpo comprende la HCDR1, la HCDR2, la HCDR3, la LCDR1, la LCDR2 y la LCDR3 de: a) la VH de la sec. con num. de ident.: 14 y la VL de la sec. con num. de ident.: 15; b) la VH de la sec. con num. de ident.: 16 y la VL de la sec. con num. de ident.: 17; c) la VH de la sec. con num. de ident.: 18 y la VL de la sec. con num. de ident.: 19; d) la VH de la sec. con num. de ident.: 20 y la VL de la sec. con num. de ident.: 21. Tambien se refiere a la administracion de la cantidad terapeuticamente eficaz del anticuerpo y tratamiento de pacientes que tienen tumores solidos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562184018P | 2015-06-24 | 2015-06-24 | |
US201562249546P | 2015-11-02 | 2015-11-02 | |
US201562250566P | 2015-11-04 | 2015-11-04 | |
US201562263307P | 2015-12-04 | 2015-12-04 | |
US201662331489P | 2016-05-04 | 2016-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20181090A1 true PE20181090A1 (es) | 2018-07-09 |
Family
ID=57586547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017002833A PE20181090A1 (es) | 2015-06-24 | 2016-06-24 | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 |
Country Status (38)
Country | Link |
---|---|
US (1) | US20160376373A1 (es) |
EP (2) | EP3313441B1 (es) |
JP (3) | JP7041519B2 (es) |
KR (2) | KR102713847B1 (es) |
CN (1) | CN107921120A (es) |
AU (1) | AU2016281717B2 (es) |
BR (1) | BR112017027990A2 (es) |
CA (1) | CA2990620A1 (es) |
CL (2) | CL2017003275A1 (es) |
CO (1) | CO2017013332A2 (es) |
DK (1) | DK3313441T5 (es) |
DO (1) | DOP2017000305A (es) |
EA (1) | EA037548B1 (es) |
EC (1) | ECSP17084878A (es) |
ES (1) | ES2982292T3 (es) |
FI (1) | FI3313441T3 (es) |
GT (1) | GT201700286A (es) |
HK (1) | HK1254942A1 (es) |
HR (1) | HRP20240338T1 (es) |
HU (1) | HUE066300T2 (es) |
IL (1) | IL256248A (es) |
LT (1) | LT3313441T (es) |
MA (1) | MA71262A (es) |
MD (1) | MD3313441T2 (es) |
MX (3) | MX2018000261A (es) |
MY (1) | MY193727A (es) |
NI (1) | NI201700170A (es) |
PE (1) | PE20181090A1 (es) |
PH (1) | PH12017502311A1 (es) |
PL (1) | PL3313441T3 (es) |
PT (1) | PT3313441T (es) |
RS (1) | RS65347B1 (es) |
SI (1) | SI3313441T1 (es) |
SM (1) | SMT202400127T1 (es) |
SV (1) | SV2017005607A (es) |
UA (1) | UA124799C2 (es) |
WO (1) | WO2016210223A1 (es) |
ZA (1) | ZA201800476B (es) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7829673B2 (en) * | 2005-03-23 | 2010-11-09 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
LT2580243T (lt) | 2010-06-09 | 2020-01-27 | Genmab A/S | Antikūnai prieš žmogaus cd38 |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
EP3620473A1 (en) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Novel heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
EP3122173B2 (en) | 2014-03-26 | 2024-05-29 | SCR Engineers Ltd | Livestock location system |
ME03666B (me) | 2014-03-28 | 2020-10-20 | Xencor Inc | Bispecifična antitela koja se vezuju za cd38 i cd3 |
US11071279B2 (en) | 2014-09-05 | 2021-07-27 | Intervet Inc. | Method and system for tracking health in animal populations |
US10986817B2 (en) | 2014-09-05 | 2021-04-27 | Intervet Inc. | Method and system for tracking health in animal populations |
PE20170676A1 (es) | 2014-09-09 | 2017-05-22 | Janssen Biotech Inc | Terapias de combinacion con anticuerpos anti-cd38 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
KR102689285B1 (ko) | 2014-11-26 | 2024-07-31 | 젠코어 인코포레이티드 | Cd3 및 종양 항원과 결합하는 이종이량체 항체 |
JP2017536830A (ja) | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd3及びcd38に結合するヘテロ二量体抗体 |
IL307913A (en) | 2014-12-04 | 2023-12-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of acute myeloid leukemia |
PE20180671A1 (es) | 2015-05-20 | 2018-04-19 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematologicas positivas para cd38 |
PE20181323A1 (es) | 2015-06-22 | 2018-08-14 | Janssen Biotech Inc | Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
TWI838196B (zh) | 2015-11-03 | 2024-04-01 | 美商健生生物科技公司 | 抗cd38抗體之皮下調配物及其用途 |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
CN108473584B (zh) | 2015-11-03 | 2022-01-14 | 詹森生物科技公司 | 特异性结合pd-1和tim-3的抗体及其用途 |
WO2017100372A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
MY195089A (en) | 2016-05-27 | 2023-01-10 | Agenus Inc | Anti-Tim-3 Antibodies and Methods of use thereof |
EP4257613A3 (en) | 2016-06-14 | 2023-12-13 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
JP7021127B2 (ja) | 2016-06-28 | 2022-02-16 | ゼンコア インコーポレイテッド | ソマトスタチン受容体2に結合するヘテロ二量体抗体 |
MX2019008241A (es) * | 2017-01-09 | 2019-12-09 | Biomunex Pharmaceuticals | Un enlazador polipeptídico para preparar anticuerpos multispecíficos. |
AU2018212652B2 (en) * | 2017-01-26 | 2024-03-28 | Sangamo Therapeutics, Inc. | B-cell engineering |
WO2018224685A1 (en) | 2017-06-08 | 2018-12-13 | Tusk Therapeutics Ltd | Cd38 modulating antibody |
KR102770104B1 (ko) * | 2017-06-08 | 2025-02-21 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
WO2018224682A1 (en) | 2017-06-08 | 2018-12-13 | Tusk Therapeutics Ltd | Cd38 modulating antibody |
EP3434692A1 (en) * | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
CN111032086B (zh) | 2017-08-16 | 2023-09-26 | 黑带医疗有限公司 | Cd38抗体 |
CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
WO2019204462A2 (en) | 2018-04-17 | 2019-10-24 | Celldex Therapeutics, Inc. | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs |
US11832584B2 (en) | 2018-04-22 | 2023-12-05 | Vence, Corp. | Livestock management system and method |
JP7526717B2 (ja) | 2018-07-13 | 2024-08-01 | ジェンマブ エー/エス | Cd38抗体のバリアントおよびその使用 |
WO2020012038A1 (en) | 2018-07-13 | 2020-01-16 | Genmab A/S | Trogocytosis-mediated therapy using cd38 antibodies |
CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
AU2019351267A1 (en) * | 2018-09-27 | 2021-05-13 | Musc Foundation For Research Development | Pharmaceutical combination for the treatment of cancer |
IL309302B2 (en) | 2018-10-10 | 2024-11-01 | Scr Eng Ltd | Livestock dry off method and device |
BR112021015531A2 (pt) | 2019-02-08 | 2021-10-26 | Allflex Australia Pty Ltd | Determinar a localização de um animal |
WO2020160589A1 (en) | 2019-02-08 | 2020-08-13 | Allflex Australia Pty Ltd | Electronic animal identification tag reader synchronisation |
AU2019428486A1 (en) | 2019-02-08 | 2021-08-26 | Allflex Australia Pty Ltd | Electronic animal tag reader |
WO2020194241A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses |
EP4090366A1 (en) | 2020-01-16 | 2022-11-23 | Genmab A/S | Formulations of cd38 antibodies and uses thereof |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
IL275518B (en) | 2020-06-18 | 2021-10-31 | Scr Eng Ltd | Animal tag |
USD990062S1 (en) | 2020-06-18 | 2023-06-20 | S.C.R. (Engineers) Limited | Animal ear tag |
USD990063S1 (en) | 2020-06-18 | 2023-06-20 | S.C.R. (Engineers) Limited | Animal ear tag |
IL275812B (en) | 2020-07-01 | 2022-01-01 | Scr Eng Ltd | System and method for placing devices |
JP2023538891A (ja) | 2020-08-19 | 2023-09-12 | ゼンコア インコーポレイテッド | 抗cd28組成物 |
WO2022113062A1 (en) | 2020-11-25 | 2022-06-02 | Scr Engineers Ltd. | A system and method for tracing members of an animal population |
JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるltbrアゴニスト |
CA3204187A1 (en) | 2021-01-14 | 2022-07-21 | Stefan Steidl | Anti-cd38 antibodies and their uses |
IL280374B2 (en) | 2021-01-24 | 2023-11-01 | Scr Eng Ltd | System and method for controlling animal marking |
TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗cd38抗體 |
CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
CA206812S (en) | 2021-04-08 | 2023-04-11 | Chevillot Sas | Tag applicator for animals |
CA206747S (en) | 2021-04-08 | 2024-12-30 | Chevillot Sas | Tag applicator for animals |
CN114805582B (zh) * | 2022-06-29 | 2022-10-04 | 上海恒润达生生物科技股份有限公司 | 抗Trop2纳米抗体及其用途 |
WO2024094660A1 (en) | 2022-10-31 | 2024-05-10 | Genmab A/S | Cd38 antibodies and uses thereof |
WO2024126750A1 (en) * | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Methods for treating cancer |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
DE602004024041D1 (de) | 2003-03-05 | 2009-12-24 | Halozyme Inc | Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen |
WO2004111233A1 (ja) | 2003-06-11 | 2004-12-23 | Chugai Seiyaku Kabushiki Kaisha | 抗体の製造方法 |
EP1720907B1 (en) | 2004-02-06 | 2015-04-08 | MorphoSys AG | Anti-cd38 human antibodies and uses therefor |
US7829673B2 (en) * | 2005-03-23 | 2010-11-09 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
ES2592271T3 (es) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos |
CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
US20090123950A1 (en) | 2005-05-24 | 2009-05-14 | Morphosys Ag | Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38 |
CN103554259B (zh) | 2005-10-12 | 2016-05-18 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
JP5474531B2 (ja) | 2006-03-24 | 2014-04-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 操作されたヘテロ二量体タンパク質ドメイン |
US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
WO2008073160A2 (en) * | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
ME03503B (me) * | 2006-09-26 | 2020-04-20 | Genmab As | Anti-cd38 plus kortkosteroidni plus ne-kortikosteroidni hemoterapeutik za tretiranje tumora |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN101802015B (zh) | 2007-03-29 | 2015-05-06 | 根马布股份公司 | 双特异性抗体及其制造方法 |
PL2170959T3 (pl) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1 |
EP2231904B1 (en) | 2007-12-19 | 2016-01-13 | Janssen Biotech, Inc. | Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
KR20110014607A (ko) | 2008-04-29 | 2011-02-11 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
SI2342226T1 (sl) | 2008-09-26 | 2016-11-30 | Dana-Farber Cancer Institute Inc. | Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe |
EP3929216A1 (en) | 2008-12-09 | 2021-12-29 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
ES2708124T3 (es) | 2009-04-27 | 2019-04-08 | Oncomed Pharm Inc | Procedimiento para preparar moléculas heteromultiméricas |
CN102918058B (zh) | 2009-11-24 | 2015-05-20 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
BR122021015749B1 (pt) | 2010-04-20 | 2022-07-26 | Genmab A/S | Métodos in vitro para gerar uma proteína heterodimérica, para a seleção de um anticorpo biespecífico, método para produzir uma proteína heterodimérica, vetor de expressão, célula hospedeira procariótica, proteína heterodimérica, composição farmacêutica, e, uso de uma proteína heterodimérica |
US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
LT2580243T (lt) * | 2010-06-09 | 2020-01-27 | Genmab A/S | Antikūnai prieš žmogaus cd38 |
EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
MX352929B (es) | 2010-11-05 | 2017-12-13 | Zymeworks Inc | DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc. |
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
EP3309175A1 (en) * | 2012-05-15 | 2018-04-18 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
US9179480B2 (en) | 2012-07-24 | 2015-11-03 | Telefonaktiebolaget L M Ericsson (Publ) | Apparatus and method for dynamically selecting a random access response window value for use with random access procedures in a network |
US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
WO2014068114A1 (en) * | 2012-11-05 | 2014-05-08 | Morphosys Ag | Radiolabelled antibody and uses thereof |
SG11201508923VA (en) | 2013-04-29 | 2015-11-27 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
US20140356318A1 (en) * | 2013-05-28 | 2014-12-04 | Israel Barken | Adoptive cell therapy with specific regulatory lymphocytes |
EP3004169B1 (en) | 2013-05-31 | 2023-03-22 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
US20160235842A1 (en) * | 2013-07-15 | 2016-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Medical uses of cd38 agonists |
JP2016536361A (ja) * | 2013-11-06 | 2016-11-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cd33抗体及び脱メチル剤を含む医薬配合物 |
US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
-
2016
- 2016-06-24 FI FIEP16815351.8T patent/FI3313441T3/fi active
- 2016-06-24 AU AU2016281717A patent/AU2016281717B2/en active Active
- 2016-06-24 EP EP16815351.8A patent/EP3313441B1/en active Active
- 2016-06-24 HU HUE16815351A patent/HUE066300T2/hu unknown
- 2016-06-24 PT PT168153518T patent/PT3313441T/pt unknown
- 2016-06-24 EP EP24158614.8A patent/EP4385569A3/en active Pending
- 2016-06-24 KR KR1020187001612A patent/KR102713847B1/ko active Active
- 2016-06-24 UA UAA201800631A patent/UA124799C2/uk unknown
- 2016-06-24 MX MX2018000261A patent/MX2018000261A/es unknown
- 2016-06-24 MD MDE20180463T patent/MD3313441T2/ro unknown
- 2016-06-24 PE PE2017002833A patent/PE20181090A1/es unknown
- 2016-06-24 US US15/191,808 patent/US20160376373A1/en not_active Abandoned
- 2016-06-24 KR KR1020247032639A patent/KR20240150522A/ko active Pending
- 2016-06-24 MA MA71262A patent/MA71262A/fr unknown
- 2016-06-24 MY MYPI2017704935A patent/MY193727A/en unknown
- 2016-06-24 JP JP2017566768A patent/JP7041519B2/ja active Active
- 2016-06-24 PL PL16815351.8T patent/PL3313441T3/pl unknown
- 2016-06-24 BR BR112017027990-8A patent/BR112017027990A2/pt active Search and Examination
- 2016-06-24 SI SI201631806T patent/SI3313441T1/sl unknown
- 2016-06-24 WO PCT/US2016/039165 patent/WO2016210223A1/en active Application Filing
- 2016-06-24 CA CA2990620A patent/CA2990620A1/en active Pending
- 2016-06-24 RS RS20240308A patent/RS65347B1/sr unknown
- 2016-06-24 LT LTEPPCT/US2016/039165T patent/LT3313441T/lt unknown
- 2016-06-24 SM SM20240127T patent/SMT202400127T1/it unknown
- 2016-06-24 DK DK16815351.8T patent/DK3313441T5/da active
- 2016-06-24 HR HRP20240338TT patent/HRP20240338T1/hr unknown
- 2016-06-24 CN CN201680048975.9A patent/CN107921120A/zh active Pending
- 2016-06-24 EA EA201890131A patent/EA037548B1/ru unknown
- 2016-06-24 ES ES16815351T patent/ES2982292T3/es active Active
-
2017
- 2017-12-11 IL IL256248A patent/IL256248A/en unknown
- 2017-12-14 PH PH12017502311A patent/PH12017502311A1/en unknown
- 2017-12-19 CL CL2017003275A patent/CL2017003275A1/es unknown
- 2017-12-20 NI NI201700170A patent/NI201700170A/es unknown
- 2017-12-21 DO DO2017000305A patent/DOP2017000305A/es unknown
- 2017-12-22 CO CONC2017/0013332A patent/CO2017013332A2/es unknown
- 2017-12-22 SV SV2017005607A patent/SV2017005607A/es unknown
- 2017-12-26 GT GT201700286A patent/GT201700286A/es unknown
- 2017-12-26 EC ECIEPI201784878A patent/ECSP17084878A/es unknown
-
2018
- 2018-01-08 MX MX2021012133A patent/MX2021012133A/es unknown
- 2018-01-08 MX MX2021012134A patent/MX2021012134A/es unknown
- 2018-01-23 ZA ZA2018/00476A patent/ZA201800476B/en unknown
- 2018-11-02 HK HK18114045.6A patent/HK1254942A1/zh unknown
-
2019
- 2019-12-13 CL CL2019003657A patent/CL2019003657A1/es unknown
-
2022
- 2022-02-03 JP JP2022015442A patent/JP7532428B2/ja active Active
-
2024
- 2024-07-30 JP JP2024123110A patent/JP2024153803A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
JP2015530399A5 (es) | ||
PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
NZ731735A (en) | Anti-pd-1 antibodies and methods of use thereof | |
PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
RU2015110981A (ru) | Комбинации и их применение | |
PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
PE20170935A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
MX389805B (es) | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. | |
PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
PE20150025A1 (es) | Anticuerpos e inmunoconjugados contra ly6e y metodos de uso | |
DOP2016000133A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
AR096687A1 (es) | Anticuerpos anti-fcrh5 | |
PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
PE20170953A1 (es) | ANTICUERPOS ANTI-CD79b Y METODOS DE USO | |
WO2017031458A3 (en) | Anti-dll3 antibody drug conjugates and methods of use |